Bisphosphonate-Related Osteonecrosis of the Jaw Associated With Dental Implants

Journal of Oral and Maxillofacial Surgery

Volumn 68, Issue 4, 2010, Pages 790-796

  Lazarovici, Towy Sorel ^a   Yahalom, Ran ^a   Taicher, Shlomo ^a   Schwartz Arad, Devorah ^b   Peleg, Oren ^a   Yarom, Noam ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b Schwartz Arad Surgical Center   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; DOXYCYCLINE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

AGED; ARTICLE; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAW OSTEONECROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXILLOFACIAL SURGERY; ORAL SURGERY; OUTCOME ASSESSMENT; SURGICAL TECHNIQUE; TOOTH IMPLANTATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; BONE DENSITY CONSERVATION AGENTS; DENTAL IMPLANTATION, ENDOSSEOUS; DENTAL IMPLANTS; DEVICE REMOVAL; DIPHOSPHONATES; DOXYCYCLINE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77949650870     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.09.017     Document Type: Article

References (48)

1. Kanis J.A., Gertz B.J., and Singer F. Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5 (1995) 1
2. Rogers M.J., Watts D.J., and Russell R.G. Overview of bisphosphonates. Cancer 80 (1997) 165
3. Body J.J., Lortholary A., Romieu G., et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14 (1999) 1557
4. Boissier S., Ferreras M., Peyruchaud O., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60 (2000) 2949
5. Jantunen E. Bisphosphonate therapy in multiple myeloma: Past, present, future. Eur J Haematol 6 (2002) 257
6. Glover D., Lipton A., Keller A., et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74 (1994) 2949
7. Lipton A. Zoledronate in the treatment of osteolytic bone metastases. Br J Clin Pract Suppl 87 (1996) 21
8. Clézardin P. The antitumor potential of bisphosphonates. Semin Oncol 29 (2002) 33
9. Li E.C., and Davis L.E. Zoledronic acid: A new parenteral bisphosphonate. Clin Ther 25 (2003) 2669
10. Liberman U.A., Weiss S.R., Bröll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 (1995) 1437
11. Gertz B.J., Holland S.D., Kline W.F., et al. Clinical pharmacology of alendronate sodium. Osteoporos Int 3 (1993) S13
12. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
13. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19 (2008) 733
14. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104
15. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
16. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
17. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
18. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99
19. Elad S., Yarom N., Hamed W., et al. Osteomyelitis and necrosis of the jaw in patients treated with bisphosphonates: A comparative study focused on multiple myeloma. Clin Lab Haematol 28 (2006) 393
20. Migliorati C.A., Casiglia J., Epstein J., et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 136 (2005) 1658
21. Wang E.P., Kaban L.B., Strewler G.J., et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65 (2007) 1328
22. Migliorati C.A., Schubert M.M., Peterson D.E., et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83
23. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
24. Mavrokokki T., Cheng A., Stein B., et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415
25. Abu-Id M.H., Warnke P.H., Gottschalk J., et al. "Bis-phossy jaws"-High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36 (2008) 95
26. Lazarovici T., Yahalom R., Taicher S., et al. Bisphosphonate-related osteonecrosis of the jaws: A single-center study of 101 patients. J Oral Maxillofac Surg 67 (2009) 850
27. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397
28. Brooks J.K., Gilson A.J., Sindler A.J., et al. Osteonecrosis of the jaws associated with use of risedronate: Report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 (2007) 780
29. Starck W.J., and Epker B.N. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: A case report. Int J Oral Maxillofac Implants 10 (1995) 74
30. Fugazzotto P.A., Lightfoot W.S., and Jaffin R. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: Postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol 78 (2007) 1664
31. Grant B.T., Amenedo C., and Freeman K. Outcomes of placing dental implants in patients taking oral bisphosphonates: A review of 115 cases. J Oral Maxillofac Surg 66 (2008) 223
32. Bell B.M., and Bell R.E. Oral bisphosphonates and dental implants: A retrospective study. J Oral Maxillofac Surg 66 (2008) 1022
33. Jeffcoat M.K. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants 21 (2006) 349
34. Jeffcoat M.K., Cizza G., Shih W.J., et al. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol 9 (2007) 70
35. Menezes A.M., Rocha F.A., Chaves H.V., et al. Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. J Periodontol 76 (2005) 1901
36. Anonymous. Alendronate may enhance implant osseointegration, study finds. J Am Dent Assoc 139 (2008) 679
37. Giro G., Sakakura C.E., Gonçalves D., et al. Effect of 17beta-estradiol and alendronate on the removal torque of osseointegrated titanium implants in ovariectomized rats. J Periodontol 78 (2007) 1316
38. Duarte P.M., de Vasconcelos Gurgel B.C., Sallum A.W., et al. Alendronate therapy may be effective in the prevention of bone loss around titanium implants inserted in estrogen-deficient rats. J Periodontol 76 (2005) 107
39. Meraw S.J., Reeve C.M., and Wollan P.C. Use of alendronate in peri-implant defect regeneration. J Periodontol 70 (1999) 151
40. Edwards B.J., Hellstein J.W., Jacobsen P.L., et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. American Dental Association Council on Scientific Affairs Expert Panel on bisphosphonate-associated osteonecrosis of the jaw. J Am Dent Assoc 139 (2008) 1674
41. Scully C., Madrid C., and Bagan J. Dental endosseous implants in patients on bisphosphonate therapy. Implant Dent 15 (2006) 212
42. Wessel J.H., Dodson T.B., and Zavras A.I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study. J Oral Maxillofac Surg 66 (2008) 625
43. Yarom N., Yahalom R., Shoshani Y., et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18 (2007) 1363
44. Varas-Lorenzo C., Rueda de Castro A.M., Maguire A., et al. Prevalence of glucose metabolism abnormalities and cardiovascular co-morbidity in the US elderly adult population. Pharmacoepidemiol Drug Saf 15 (2006) 317
45. Forouhi N.G., Merrick D., Goyder E., et al. Diabetes prevalence in England, 2001-Estimates from an epidemiological model. Diabet Med 23 (2006) 189
46. Pautke C., Bauer F., Tischer T., et al. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67 (2009) 471
47. Lindsay R., Cosman F., Zhou H., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J Bone Miner Res 21 (2006) 366
48. Pautke C., Tischer T., Neff A., et al. In vivo tetracycline labeling of bone: An intraoperative aid in the surgical therapy of osteoradionecrosis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) e10